TECX - Tectonic Therapeutic, Inc.
About Tectonic Therapeutic, Inc. (https://tectonictx.com)
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Alise S. Reicin | President, Chief Executive Officer, Secretary & Director | 1961 | $1,031,108 USD |
| Daniel Lochner | Chief Financial Officer | 1983 | $728,712 USD |
| Marcella K. Ruddy | Chief Medical Officer | 1964 | $723,250 USD |
| Anthony Muslin | Chief Development Officer | – | – |
| Geraldine Peters-Wiles | Senior Vice President of Human Resources | – | – |
| John Diener | Senior Vice President of Antibody Engineering & Protein Sciences | – | – |
| Marc Schwabish | Chief Business Officer | 1980 | – |
| Peter McNamara | Chief Scientific Officer | 1972 | – |
| Washington Alves | Senior Vice President of Technical Operations | – | – |